Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$18 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-3.6 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
3
Industry P/E
--
EV/EBITDA
-0.4
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-2572.8
Face value
--
Shares outstanding
4,245,710
CFO
$-57.69 Mln
EBITDA
$-77.14 Mln
Net Profit
$-80.85 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Cingulate Inc (CING)
| -18.3 | 14.2 | 1.8 | -42.1 | -77.4 | -- | -- |
|
BSE Sensex
| 4.7 | 1.2 | 6.5 | 6.1 | 16.5 | 18.6 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
|---|---|---|---|
|
Cingulate Inc (CING)
| -94.5 | -61.8 | -63.8 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Cingulate Inc (CING)
|
4.0 | 17.6 | 0.0 | -7,043.6 | -- | -237 | -- | 3.0 |
| 49.2 | 7,861.9 | 1,208.8 | 131.7 | 13.4 | 6.3 | 60.1 | 3.9 | |
| 128.2 | 8,285.0 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 24.2 | |
| 146.8 | 7,242.1 | 4,022.6 | -31.6 | 3.7 | -1.1 | -- | 2.3 | |
| 52.0 | 10,001.6 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.1 | |
| 44.3 | 11,009.2 | 2,298.9 | 643.6 | 35.4 | 29.2 | 18.4 | 5.2 | |
| 52.7 | 6,507.3 | 1,084.3 | 485.4 | 57.0 | 103.8 | 14 | 13.5 | |
| 312.1 | 8,699.8 | 2,156.6 | 416.4 | 21.2 | 56.5 | 23.1 | 14.7 | |
| 25.6 | 10,016.6 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.0 | |
| 127.1 | 12,524.1 | 2,412.6 | 305.8 | 20.5 | 11.6 | 42.9 | 5.0 |
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company develops medications capable of once-daily dosing using... its proprietary drug delivery platform technology, Precision Timed Release. Its drug candidates include CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials, as well as CTx-1302 (dextroamphetamine), which is in Phase 1/2 clinical pharmacology and Phase 3 clinical efficacy and safety trials for the treatment of ADHD in children, adolescents, and adults; and CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and related disorders. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas. Read more
CEO & Chairman of the Board
Dr. Shane J. Schaffer Pharm.D., PharmD
CEO & Chairman of the Board
Dr. Shane J. Schaffer Pharm.D.
Headquarters
Kansas City, KS
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Cingulate Inc (CING) stood at $ 22,970 Mln as on 31-Mar-25
The share price of Cingulate Inc (CING) is $4.03 (NASDAQ) as of 23-Jun-2025 13:38 EDT. Cingulate Inc (CING) has given a return of -77.43% in the last 3 years.
Cingulate Inc (CING) has a market capitalisation of $ 18 Mln as on 20-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Cingulate Inc (CING) is 2.97 times as on 20-Jun-2025, a 6% premium to its peers’ median range of 2.79 times.
Since, TTM earnings of Cingulate Inc (CING) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Cingulate Inc (CING) and enter the required number of quantities and click on buy to purchase the shares of Cingulate Inc (CING).
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company develops medications capable of once-daily dosing using its proprietary drug delivery platform technology, Precision Timed Release. Its drug candidates include CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials, as well as CTx-1302 (dextroamphetamine), which is in Phase 1/2 clinical pharmacology and Phase 3 clinical efficacy and safety trials for the treatment of ADHD in children, adolescents, and adults; and CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and related disorders. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
The CEO & director of Dr. Shane J. Schaffer Pharm.D., PharmD. is Cingulate Inc (CING), and CFO & Sr. VP is Dr. Shane J. Schaffer Pharm.D..
There is no promoter pledging in Cingulate Inc (CING).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,260
|
|
|
1,128
|
|
|
991
|
|
|
988
|
|
|
870
|
|
|
829
|
|
|
809
|
|
|
742
|
|
|
664
|
| Cingulate Inc (CING) | Ratios |
|---|---|
|
Return on equity(%)
|
-237.05
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Cingulate Inc (CING) was $0 Mln.
$-0.11
(
